Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
-
SciScore for 10.1101/2021.01.13.426626: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All animal studies were approved by the Institutional Animal Ethics committee (IAEC) (RR/IAEC/61-2019, Invivo/GP/084).
IRB: The ethics approval of human clinical samples were approved by Institute Human Ethical Committee (Approval No: CSIR-IGIB/IHEC/2020-21/01) CPE based viral Neutralization assay: Mice and Guinea pig pre-immune (negative control) sera and post boost sera were assayed for virus neutralization.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Mice and Guinea Pig Immunizations: Immunizations of BALBc mice (n=5/group, female, 3-4 weeks old, ∼16-18 g) and Hartley strain guinea pigs … SciScore for 10.1101/2021.01.13.426626: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All animal studies were approved by the Institutional Animal Ethics committee (IAEC) (RR/IAEC/61-2019, Invivo/GP/084).
IRB: The ethics approval of human clinical samples were approved by Institute Human Ethical Committee (Approval No: CSIR-IGIB/IHEC/2020-21/01) CPE based viral Neutralization assay: Mice and Guinea pig pre-immune (negative control) sera and post boost sera were assayed for virus neutralization.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Mice and Guinea Pig Immunizations: Immunizations of BALBc mice (n=5/group, female, 3-4 weeks old, ∼16-18 g) and Hartley strain guinea pigs (n=5/group, female, 6-8 weeks old, ∼300 g) were performed with freshly adjuvanted (AddaVax™ (vac-adx-10)) protein (1:1 v/v Antigen : AddaVax™ ratio per animal/dose, 20 µg protein in 50 µl PBS (pH 7.4) and 50 µl AddaVax™) (InvivoGen, USA). Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Trimeric RBD, ACE2-hFc and antibody expression constructs: The present trimeric mRBD construct consists of an N-terminal trimerization domain of human cartilage matrix protein (hCMP) (hCMP residues 298-340) (accession number AAA63904) linked by a 14-residue flexible linker (ASSEGTMMRGELKN) derived from the V1 loop of HIV-1 JR-FL gp120 linked to RBD residues 332-532 (accession number YP_009724390.1) with an engineered glycosylation site (NGS) at N532 fused to an HRV-3C precision protease cleavage site linked to a 10x Histidine tag by a GS linker. gp120suggested: (Fitzgerald Industries International Cat# 10R-G114a, RRID:AB_1285924)The expression levels were checked using a dot blot analysis with Anti-his tag antibodies conjugated with HRP enzyme. Anti-his tagsuggested: NoneSPR-binding of hCMP-mRBD analyte to immobilized ACE2-hFc/CR3022: hCMP-mRBD protein kinetic binding studies to ACE2-hFc and CR3022 antibody were performed on a ProteOn XPR36 Protein Interaction Array V.3.1 (Bio-Rad). CR3022suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)Next, three washes were performed (200 µL of PBST/well) and anti-Human IgG secondary antibody (Sigma-Aldrich) anti-Human IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Generation of adherent polyclonal Flp-In stable lines: T25 flasks (5 ml media) having either adherent Flp-In™-293 or Flp-In™-CHO cells (∼80 % confluent) were co-transfected with pOG44 (10 µg) and hCMP-mRBD-HRV-Tg-pcDNA5/FRT/TO (5µg) plasmid DNA using 35 µg of Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher Scientific, Cat # 11668030) in serum free media as per the manufacturers instruction for 4 hr. Flp-Insuggested: RRID:CVCL_U423)(Thermofisher Scientific Cat# 10687010) for Flp-In™-293 and 750 µg/ ml for Flp-In™-CHO cells. Flp-In™-293suggested: RRID:CVCL_U421)Tagless protein purification: The spent media from stable hCMP-mRBD-HRV-Tg-Flp-In™-293 or Flp-In™-CHO grown cells contained the expressed protein. Flp-In™-CHOsuggested: RRID:CVCL_U424)The virus-serum incubated premix samples were serially diluted and plated in duplicates in VeroE6 cell containing 96 well plate (104/well) and cultured for 48/96 hours. VeroE6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Briefly, HEK293T cells were transiently transfected with plasmid DNA pHIV-1 NL4.3Δenv-Luc and Spike-Δ19-D614G by using Profection mammalian transfection kit (Promega Inc) following the instructions in the kit manual. HEK293Tsuggested: NonePatient derived convalescent sera (n = 40) were tested for neutralization in both 293T-ACE-2 and Vero/TMPRSS2 cells whereas animal sera were tested only in Vero/TMPRSS2 cells. Vero/TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)The correlation coefficients for ACE2-hFc receptor competition, pseudovirus, live virus and 293T-ACE2/VeroE6-TMPRSS2 cell line pseudovirus neutralizations were analysed by Spearman correlation using the GraphPad Prism software. 293T-ACE2/VeroE6-TMPRSS2suggested: NoneSoftware and Algorithms Sentences Resources The unbound tagless proteins concentration was determined by absorbance (A280) using NanoDrop™2000c with the theoretical molar extinction coefficient calculated using the ProtParam tool (ExPASy) ProtParamsuggested: (ProtParam Tool, RRID:SCR_018087)ExPASysuggested: NoneReference-free 2D classification using single-particle analysis: The evaluation of micrographs was done with EMAN 2.1 (58). EMANsuggested: (EMAN, RRID:SCR_016867)Reference free 2D classification of different projections of particle were calculated using simple_prime2D of SIMPLE 2.1 software (59). SIMPLEsuggested: (SIMPLE, RRID:SCR_009389)Statistical Analysis: The p values for ELISA binding titers, neutralization titers, ACE2 receptor competition titers were analysed with a two-tailed Mann-Whitney test using the GraphPad Prism software. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-